Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado, Takeo Kosaka, Walter M. Stadler, Lisa G. Horvath, Richard Greil, Bert H. O’Neil, Bilal A. Siddiqui, Thomas Bauernhofer, Mehmet Asım Bilen, Ferry A.L.M. Eskens, Shahneen Sandhu, Crystal Shaw, Changqing Ju, Benjamin E. Decato, Brian Yu, Ana M. Aparicio (2025). Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. , DOI: https://doi.org/10.1158/1078-0432.ccr-25-1211.
Article313 days agoSafety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado, Takeo Kosaka, Walter M. Stadler, Lisa G. Horvath, Richard Greil, Bert H. O’Neil, Bilal A. Siddiqui, Thomas Bauernhofer, Mehmet Asım Bilen, Ferry A.L.M. Eskens, Shahneen Sandhu, Crystal Shaw, Changqing Ju, Benjamin E. Decato, Brian Yu, Ana M. Aparicio (2025). Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. , DOI: https://doi.org/10.1158/1078-0432.ccr-25-1211.
Article313 days agoPhase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado-González, Takeo Kosaka, Walter M. Stadler, Shahneen Sandhu, Brian Yu, Crystal Shaw, Chia‐Hsin Ju, Corbin G. Thompson, Ana M. Aparicio (2024). Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).. , 42(16_suppl), DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.5012.
Article313 days agoPhase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Rahul Aggarwal, Sylvie Rottey, Ana M. Aparicio, Richard Greil, Melissa A. Reimers, Shahneen Sandhu, Yiran Zhang, Mark Salvati, Nooshin Hashemi Sadraei (2022). Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).. , 40(6_suppl), DOI: https://doi.org/10.1200/jco.2022.40.6_suppl.tps197.
Article313 days agoErdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schüler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Josep Tabernero, David A. Reardon, Christophe Massard, Anna Minchom, Iwona Ługowska, Omar Carranza, Dirk Arnold, Martin Gutierrez, Helen Winter, Kim Stuyckens, Lauren Crow, Saltanat Najmi, Constance Hammond, Shibu Thomas, Ademi Santiago-Walker, Spyros Triantos, Hussein Sweiti, Yohann Loriot, Omar Carranza, Martin Alberto Greco, Jermaine Coward, Anthony M. Joshua, Christos S. Karapetis, Christopher D. Hart, Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang (2023). Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. , 24(8), DOI: https://doi.org/10.1016/s1470-2045(23)00275-9.
Article58 days ago